Biotech group’s shares hit by weight-loss drug setback
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
Zealand Pharma chief says next-generation obesity drugs will need to be longer lasting and better tolerated
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Once-a-week injection achieved less weight loss than rival treatment
Outcome is blow to one of Europe’s largest listed companies
